[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346078-105":59,"doc-detail-346078-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","bioinformatic-pipeline-to-identify-potential-therapeutic-targets-with-subsequent-isolation-and-characterization-of-novel-human-anti-ddr1-antibodies","Bioinformatic pipeline to identify potential therapeutic targets with subsequent isolation and characterization of novel human anti-DDR1 antibodies","","Breast cancer is a major global health challenge, motivating safer and more effective targeted therapies. This study developed an integrated bioinformatics pipeline using paired tumor and matched non-cancer breast tissues from The Cancer Genome Atlas to find dysregulated, therapeutically relevant candidates. Epithelial discoidin domain-containing receptor 1 (DDR1) was selected, and a naïve human phage display library was screened to isolate DDR1-specific single-chain fragments, reformatted into full-length IgG1. Antibodies were expressed, purified, and characterized via biophysical and in vitro assays, showing high-affinity binding and antibody-dependent cell cytotoxicity-mediated tumor cell lysis, supporting the approach’s value for new breast cancer therapies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/bioinformatic-pipeline-to-identify-potential-therapeutic-targets-with-subsequent-isolation-and-characterization-of-novel-human-anti-ddr1-antibodies/346078/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/bioinformatic-pipeline-to-identify-potential-therapeutic-targets-with-subsequent-isolation-and-characterization-of-novel-human-anti-ddr1-antibodies/346078.png","ImageObject",300,407,{"name":92,"@type":93},"Theodora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does the study identify potential breast cancer therapeutic targets?","Question",{"text":112,"@type":113},"It uses an integrated bioinformatics pipeline on TCGA paired tumor and matched non-cancer breast tissue samples, combining differential expression, target selection criteria, and surface-protein enrichment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why was DDR1 selected for antibody discovery?",{"text":117,"@type":113},"From shortlisted candidates, epithelial discoidin domain-containing receptor 1 (DDR1) was chosen to support the development of DDR1-specific therapeutic antibodies.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports the antibody candidates’ therapeutic potential?",{"text":121,"@type":113},"The isolated human IgG1 antibodies were expressed and purified, then showed high-affinity binding to native DDR1 on breast cancer cells and mediated tumor cell lysis via antibody-dependent cell cytotoxicity (ADCC).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346078,1790588061,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nBioinformatic pipeline to identify potential therapeutic targets with subsequent isolation and characterization of novel human anti-DDR1 antibodies  \nDivya Agrawal1,2,3, Stephen M. Mahler1, Anurag S. Rathore2, Martina L. Jones1􀀍, Jessica C. Mar1 & Lucía F. Zacchi1,4  \nBreast cancer remains a major global health challenge, driving the need for safer and more effective targeted therapies. This study aimed to systematically identify therapeutic targets for breast cancer using an integrated bioinformatics approach and to generate novel human monoclonal antibodies against an identified potential target followed by characterization. A multi-step bioinformatic pipeline was developed to analyse paired tumour and matched non-cancerous breast tissue samples from The Cancer Genome Atlas. Differential expression analysis, target selection criteria, and surfaceprotein enrichment identified several dysregulated and therapeutically relevant candidates, including established markers such as HER2, supporting the robustness of the approach. From the shortlisted targets, epithelial discoidin domain-containing receptor 1 was selected for antibody discovery. A naïve human phage display library was screened to isolate DDR1-specific single-chain variable fragments that were reformatted into full-length human IgG1. These antibodies were expressed, purified, and characterized through biophysical evaluation and in vitro assays. Several candidates demonstrated high-affinity binding to native DDR1 on breast cancer cells and showed the ability to mediate tumour cell lysis through antibody-dependent cell cytotoxicity. Overall, this study highlights the effectiveness of combining publicly available omics datasets with phage display technology to identify and develop new therapeutic antibody candidates for breast cancer.  \nKeywords TCGA, Biomarker identification, Omics-based therapeutic biomarker, Targeted therapy, Antibody development, Discoidin domain-containing receptor 1  \nDespite significant advances, cancer remains a challenging disease to manage. Breast cancer accounts for the highest number of new cancer cases every year in women compared to any other cancer type1. Monoclonal antibodies (mAbs) are highly effective treatments for cancer because they can precisely target cancer cells while strengthening the immune system’s response against these cancer cells2. Notable examples include rituximaband trastuzumab, which target CD20 and Her2, respectively, and have demonstrated substantial therapeutic efficacy3,4. However, although these antibodies boost a patient’s immune response to target cancer, they do not always guarantee complete remission from the disease, and these treatments are often followed by relapse with high mortality5. A key challenge for developing effective cancer therapies lies in identifying suitable tumorassociated antigens that are both highly specific to cancer cells with minimal or no expression on normal tissues to prevent off-target effects, and sufficiently exposed or accessible on the cell surface to enable effective antibody targeting6. The barriers to identifying antigens that satisfy these properties is that, in tumours, antigen expression can be heterogeneous and variable, thereby complicating the identification of reliable therapeutic  \n1Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Brisbane, QLD 4072, Australia. 2Department of Chemical Engineering, Indian Institute of Technology, New Delhi 110016, India. 3The University of Queensland-Indian Institute of Technology Delhi Research Academy (UQ-IITD RA), New Delhi 110016, India. 4School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Brisbane, QLD 4072, Australia. 􀀍 email: [martina.jones@uq.edu.au](martina.jones@uq.edu.au)  \ntargets7. To overcome these hurdles, one strategy is to combine multiple sources of input ","cbCaiuDJwnEoeXcl","https://ap.wps.com/l/cbCaiuDJwnEoeXcl","pdf",6099325,25,"English","# Introduction\n## Challenges in selecting tumor-associated antigens\n## Limitations of bioinformatics predictions\n# Integrated bioinformatics and antibody discovery\n## Differential expression and target selection\n## DDR1 selection for antibody discovery\n## Phage display screening and IgG1 reformatting\n# Antibody expression, characterization, and in vitro validation\n## Biophysical evaluation\n## In vitro assays and cell lysis through ADCC\n# Overall significance and rationale\n## Public omics with phage display for therapeutic discovery","[{\"question\":\"How does the study identify potential breast cancer therapeutic targets?\",\"answer\":\"It uses an integrated bioinformatics pipeline on TCGA paired tumor and matched non-cancer breast tissue samples, combining differential expression, target selection criteria, and surface-protein enrichment.\"},{\"question\":\"Why was DDR1 selected for antibody discovery?\",\"answer\":\"From shortlisted candidates, epithelial discoidin domain-containing receptor 1 (DDR1) was chosen to support the development of DDR1-specific therapeutic antibodies.\"},{\"question\":\"What evidence supports the antibody candidates’ therapeutic potential?\",\"answer\":\"The isolated human IgG1 antibodies were expressed and purified, then showed high-affinity binding to native DDR1 on breast cancer cells and mediated tumor cell lysis via antibody-dependent cell cytotoxicity (ADCC).\"}]","Bioinformatic pipeline to identify potential therapeutic targets with subsequent isolation and characterization of novel human anti-DDR1 antibodies | PDF",1790059971,63,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e935d4c3a59d2ada405e43d86ccff91.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90ce508d338e4a2980bfb1f7c024ad11.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58e7337f144a9385641dee36aca0739e.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23f485d9dad2fe958185f24e6a4a459a.webp",980,1287]